Adaptive biotechnologies stock.

Nov 7, 2023 · SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ... Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of t...Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive …Earlier this year, an enthusiastic market more than doubled the price of Adaptive Biotechnologies stock. Now that shares are trading around 22% below their recent peak, investors are wondering if ...

Aug 2, 2023 · SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million.Adaptive Biotechnologies Stock Performance. NASDAQ ADPT opened at $4.33 on Tuesday. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The company has a 50-day ...

Adaptive Biotechnologies Stock Performance. NASDAQ ADPT opened at $4.33 on Tuesday. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The company has a 50-day ...Nov 30, 2023 · Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ... Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose …SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.

May 3, 2023 · Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago. These ...

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. …

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter of 2023 …The stock is down 50% post the news. ... Some other top-ranked stocks in the overall healthcare sector include Adaptive Biotechnologies Corporation ADPT, ...Samples were sent overnight at ambient temperature to Adaptive Biotechnologies (Seattle, WA) for processing. Plasma was isolated within 5 days of collection. ctDNA levels were subsequently determined from isolated plasma via next-generation sequence as described. 13 Clinicians did not have these data available at the …Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

As of March 24, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.43. Adaptive Biotechnologies Corp is up 7.53% from its previous closing price of $7.84. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.79 and $8.24. Currently, there are 143.06 million shares of Adaptive ...Earlier this year, an enthusiastic market more than doubled the price of Adaptive Biotechnologies stock. Now that shares are trading around 22% below their recent peak, investors are wondering if ...The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies.Adaptive Biotechnologies Corporation (ADPT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Adaptive Biotechnologies ...Dec 1, 2022 · SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ...

View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Adaptive Biotechnologies Corporation announces a multi-year collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies. This collaboration aims to support the clinical development and potential …0.86%. $864.11M. ADPT | Complete Adaptive Biotechnologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight …Adaptive Biotechnologies ( NASDAQ: ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May. The Seattle-based life ...Nov 30, 2023Beigene Ltd (BGNE) Stock Analysis: Promising Potential in Cancer Treatment and Positive Market Sentiment. Beigene Ltd (BGNE) is a biotechnology company that has gained attention from investors due to its promising potential in the field of cancer treatment. On November 7, 2023, the stock’s performance was closely monitored by analysts and ...Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update. SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive …Track Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsStock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Adaptive is powering immune medicine in the most unique way—and we’re looking for individuals who want to build a story, not just a resume. If you want to go beyond the impossible—Adaptive is where you’ll discover your story. You’ll tackle big, interesting, highly impactful problems that lead to a future you can help write.

Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of t...

Adaptive Biotechnologies Stock Performance. NASDAQ ADPT opened at $4.33 on Tuesday. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The company has a 50-day ...Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. …Adaptive Biotechnologies ( NASDAQ: ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May. The Seattle-based life ...Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2022 and December 31, 2021; 142,784,868 and 141,393,865 shares issued and outstanding at June 30, 2022 and …Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Track Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine. SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ...SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to …Transcript : Adaptive Biotechnologies Corporation, Q4 2022 Earnings Call, Feb 14, 2023 February 14, 2023 at 04:30 pmInstagram:https://instagram. fig stockstocks iconreal estate investing appnovagold stock SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ... current interest rates az2023 most popular dog breeds Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of July 21, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.08. Adaptive Biotechnologies Corp is up 4.94% from its previous closing price of $7.70. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.60 and $7.79.On November 9, Adaptive Biotechnologies will report earnings from Q3. Wall Street analysts predict losses per share of $0.339. Track Adaptive Biotechnologies stock price in real-time ahead here ... financial planner spokane 52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. RSS Feeds.Jul 21, 2023 · Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of July 21, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.08. Adaptive Biotechnologies Corp is up 4.94% from its previous closing price of $7.70. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.60 and $7.79.